ABIVAX appoints Didier Blondel as Chief Financial Officer

Paris, December 15th, 2016 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral diseases, today announced the appointment of Didier Blondel as Chief Financial Officer, effective January 2nd, 2017.

Didier Blondel CFO ABIVAX


Mr. Blondel was Chief Financial Officer at Sanofi Pasteur MSD, a Lyon-based joint-venture between Sanofi and Merck, and European leader in human vaccines, since 2012. During the previous 20 year period, Mr. Blondel held a wide scope of senior finance positions at Sanofi, in Commercial Operations and then R&D, where he became Global R&D CFO. Didier Blondel started his career as an auditor at Price Waterhouse Coopers, after graduating from the Commercial Institute of Nancy (ICN), a leading French Business School. He also holds a Master in Finance and Accounting degree from University of Nancy, as well as a Professional Certificate in Finance and Accounting (DESCF).

Alain Chevallier, currently CFO of ABIVAX, will transition to new professional opportunities at Truffle Capital, the majority shareholder of ABIVAX. Mr. Chevallier will continue as a Senior Advisor at ABIVAX.

“I am enthusiastic to welcome Didier as Chief Financial Officer of ABIVAX. His extensive experience in Finance will be a significant addition to the ABIVAX team,” said Prof. Hartmut Ehrlich, M.D., Chief Executive Officer of ABIVAX. "And I warmly thank Alain Chevallier for bringing his unique expertise and tremendous experience to the company and his outstanding contributions in successfully enabling ABIVAX to meet critical milestones, including the company creation in 2013 and our IPO in 2015. We look forward to receiving his continuous support as Senior Advisor.”

“I am thrilled to join ABIVAX with its compelling mission, exciting development portfolio, and dynamic, exceptional team,” said Didier Blondel. “I am very much looking forward to contributing to the success of the company,” he added. 

Press contacts

Caroline Carmagnol 


+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41